Osseon Therapeutics, Inc., a company that focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease, has entered into an International Distribution Agreement with Aesculap AG, a division of B Braun Melsungen, to distribute its vertebral compression fracture (VCF) treatment devices, including its new CE-Mark approved device – Osseoflex SB (steerable balloon) in select regions of Europe and Asia.  

Aesculap is a large medical and pharmaceutical company headquartered in Tuttlingen, Germany.  The Osseoflex SB and the other Osseon CE Mark approved VCF medical devices offer a complete platform for treatment of spinal fractures.

"Aesculap is a major medical device company known throughout the world as a quality manufacturer and distributor of surgical instruments.  Our new Osseoflex SB (steerable balloon) represents the most precise and controllable treatment device for vertebral compression fracture augmentation currently available to surgeons.  Osseon is very excited to partner with Aesculap to distribute our game-changing Osseoplasty devices and procedures for VCF treatment to patients throughout Europe and the international community and provide state-of-the-art alternatives to the cumbersome devices and procedures currently used to treat fractures of the thoracic and lumbar spine," said John Stalcup, Ph.D., Osseon's CEO.

B Braun is one of the world´s leading healthcare suppliers. Its four divisions orient their products and services toward different medical fields: hospital, surgery, private practice (medical care and doctors´ offices) and extracorporeal blood treatment.  Aesculap focuses on products and services for core processes in surgery.  Aesculap's product range includes surgical instruments for open or minimally invasive approaches, implants (e.g., for orthopaedics, neurosurgery and spinal surgery), surgical sutures, sterile container, storage, motor and navigation systems as well as products for cardiology.